What is Oragenics Price-to-Operating-Cash-Flow?
As of today (2024-06-08), Oragenics's share price is $1.67.
Oragenics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.21. Hence, Oragenics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Oragenics's Price-to-Operating-Cash-Flow or its related term are showing as below:
Oragenics's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was $-0.88.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.21.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 43.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 37.40% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 31.20% per year.
During the past 13 years, Oragenics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 46.90% per year. The lowest was -1.40% per year. And the median was 26.90% per year.
Oragenics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Oragenics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oragenics Price-to-Operating-Cash-Flow Chart
|
Oragenics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Oragenics Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Oragenics's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Oragenics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oragenics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oragenics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Oragenics's Price-to-Operating-Cash-Flow falls into.
Oragenics Price-to-Operating-Cash-Flow Calculation
Oragenics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 1.67 | / | -3.213 |
| = | |
Oragenics's Share Price of today is $1.67.
Oragenics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.21.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Oragenics (Oragenics) Business Description
Traded in Other Exchanges
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634
Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.
Executives
| Fred Telling |
director |
501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119 |
| John P Gandolfo |
director |
62 TERRACE ROAD, WAYNE NJ 07470 |
| Cassidy Bruce A. Sr. |
director |
C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203 |
| Janet Huffman |
officer: CFO, Secretary and Treasurer |
5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232 |
| Robert C Koski |
director, 10 percent owner |
1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243 |
| Michael O'keefe Sullivan |
officer: CFO, Secretary and Treasurer |
3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607 |
| Joseph Hernandez |
10 percent owner |
C/O MICROLIN BIO, INC., NEW YORK NY 10022 |
| Kimberly M Murphy |
director |
101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602 |
| Koski Family Lp |
10 percent owner |
1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243 |
| Randal J Kirk |
10 percent owner |
1881 GROVE AVENUE, RADFORD VA 24141 |
| Alan Joslyn |
director, officer: CEO and President |
39 OLD RIDGEBURY ROAD, DANBURY CT 06810 |
| Charles L Pope |
director |
4902 EISENHOWER BOULEVARD, TAMPA FL 33634 |
| Christine L Koski |
director, 10 percent owner |
1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243 |
| Beverly Koski |
10 percent owner |
|
| Thomas L Koski |
10 percent owner |
|
Oragenics (Oragenics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OGEN has been successfully added to your